Reuters logo
BRIEF-Oncodesign enters into services agreement with Eisai
December 17, 2014 / 7:52 AM / 3 years ago

BRIEF-Oncodesign enters into services agreement with Eisai

Dec 17 (Reuters) - Oncodesign SA :

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

* Oncodesign could receive revenues up to 1.25 mln euros for their contribution towards total Eribulin biomarker development program, of which 0.9 mln euros have already been received

* Oncodesign will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign`s patient-derived xenograft models

* Program aims to identify useful patient stratification biomarkers for Eisai`s halaven eribulin using patient-derived xenograft models

* Program to investigate potential of Halaven Eribulin in earlier line treatment of metastatic breast cancer Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below